Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Arrhythmias

  Free Subscription


Articles published in Eur J Pharmacol

Retrieve available abstracts of 13 articles:
HTML format



Single Articles


    November 2021
  1. FANG J, Kong B, Shuai W, Xiao Z, et al
    Ferroportin-mediated ferroptosis involved in new-onset atrial fibrillation with LPS-induced endotoxemia.
    Eur J Pharmacol. 2021 Nov 5:174622. doi: 10.1016/j.ejphar.2021.174622.
    PubMed     Abstract available


    August 2021
  2. BELEM-FILHO IJA, Brasil TFS, Fortaleza EAT, Antunes-Rodrigues J, et al
    A functional selective effect of oxytocin secreted under restraint stress in rats.
    Eur J Pharmacol. 2021;904:174182.
    PubMed     Abstract available


    June 2021
  3. BAI S, Wang X, Wu H, Chen T, et al
    Cardioprotective effect of anisodamine against ischemia/reperfusion injury through the mitochondrial ATP-sensitive potassium channel.
    Eur J Pharmacol. 2021;901:174095.
    PubMed     Abstract available


    May 2021
  4. SAPONARA S, Fusi F, Iovinelli D, Ahmed A, et al
    Flavonoids and hERG channels: Friends or foes?
    Eur J Pharmacol. 2021;899:174030.
    PubMed     Abstract available


    April 2021
  5. SILVA EAP, Carvalho JS, Dos Santos DM, Oliveira AMS, et al
    Cardiovascular effects of farnesol and its beta-cyclodextrin complex in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Apr 2:174060. doi: 10.1016/j.ejphar.2021.174060.
    PubMed     Abstract available


    February 2021
  6. ZEQUN Z, Yujia W, Dingding Q, Jiangfang L, et al
    Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Eur J Pharmacol. 2021;893:173813.
    PubMed     Abstract available


    December 2020
  7. AMSTETTER D, Badt F, Rubi L, Bittner RE, et al
    The bradycardic agent ivabradine decreases conduction velocity in the AV node and in the ventricles in-vivo.
    Eur J Pharmacol. 2020 Dec 17:173818. doi: 10.1016/j.ejphar.2020.173818.
    PubMed     Abstract available


    September 2020
  8. FO Y, Zhang C, Chen X, Liu X, et al
    Chronic sigma-1 receptor activation ameliorates ventricular remodeling and decreases susceptibility to ventricular arrhythmias after myocardial infarction in rats.
    Eur J Pharmacol. 2020 Sep 30:173614. doi: 10.1016/j.ejphar.2020.173614.
    PubMed     Abstract available


    July 2020
  9. KOJIMA A, Fukushima Y, Itoh H, Imoto K, et al
    A computational analysis of the effect of sevoflurane in a human ventricular cell model of long QT syndrome: Importance of repolarization reserve in the QT-prolonging effect of sevoflurane.
    Eur J Pharmacol. 2020 Jul 22:173378. doi: 10.1016/j.ejphar.2020.173378.
    PubMed     Abstract available


    June 2020
  10. ABDULSALAM TM, Hasanin AH, Mohamed RH, El Sayed Badawy A, et al
    Angiotensin receptor-neprilysin inhibitior)thiorphan/irbesartan( decreased ischemic-reperfusion induced ventricular arrhythmias in rat; in vivo study.
    Eur J Pharmacol. 2020 Jun 25:173295. doi: 10.1016/j.ejphar.2020.173295.
    PubMed     Abstract available


    April 2020
  11. RAHM AK, Muller ME, Gramlich D, Lugenbiel P, et al
    Inhibition of cardiac Kv4.3 (Ito) channel isoforms by class I antiarrhythmic drugs lidocaine and mexiletine.
    Eur J Pharmacol. 2020 Apr 29:173159. doi: 10.1016/j.ejphar.2020.173159.
    PubMed     Abstract available


  12. LI LY, Lou Q, Liu GZ, Lv JC, et al
    Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.
    Eur J Pharmacol. 2020 Apr 20:173120. doi: 10.1016/j.ejphar.2020.173120.
    PubMed     Abstract available


    March 2020
  13. LI Q, Zhai Z, Li J
    Fibroblast growth factor homologous factors are potential ion channel modifiers associated with cardiac arrhythmias.
    Eur J Pharmacol. 2020;871:172920.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: